FORMULATION AND DEVELOPMENT OF KETOROLAC TROMETHAMINE OPHTHALMIC SOLUTION

  • Deepak Kumar Sarangi Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
  • Suman Kumar Mekap Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
  • Sagar Suman Panda Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
  • Debashish Ghose Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
  • Rabinarayan Rana Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
  • Monalisa Mahapatra Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA

Abstract

An acetic acid derivative ketorolac tromethmine has found its applicability in both gram positive and gram negative bacterial ocular infection and used commonly associated with multiple doses. Ophthalmic medication stored in multiple dose containers is required by the U.S. Food and Drug Administration to contain a preservative so that patients are provided with microbe free medication. Benzalkonium chloride in concentrations from 0.1% to 0.0001% induced dose-dependent growth arrest and conjunctiva epithelial cell death, either delayed or immediately after administration. In such case, a preservative Benzalkonium chloride must be used within reasonable bound. Benzalkonium chloride can provide more help than harm. Hence the present study focusing on to  formulate a formulation for ketorolac tromethmine (0.5%) ophthalmic solution using different concentration of Benzalkonium chloride as preservative.

Keywords: Ketorolac tromethamine, Ophthalmic, benzalkonium chloride, conjunctiva

Downloads

Download data is not yet available.

Author Biographies

Deepak Kumar Sarangi, Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
Suman Kumar Mekap, Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
Sagar Suman Panda, Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
Debashish Ghose, Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA
Rabinarayan Rana, Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA

Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA

Monalisa Mahapatra, Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA

Roland Institute of Pharmaceutical Sciences, Brahmapur, Odisha, INDIA

References

1. Baveja, S. K., Ranga – Rao, K. V. and Padmalatha Devi, K., Zero order release hydrophilic eye drops of adrenergic blockers, Int. J. Pharm., 1997; 39:39-45
2. Diao, Y. Tu, XD.,Development and pharmacokinetic study of miocamycin sustained release Ocular drug delivery system, Acta Pharmaceutica Sinica. 1991; 26 (Sep): 695-700.
3. Du, K. Chen, SX. Zhu, JB., Eye drops of zomepirac sodium with cellulose acetate.,J. of Pharm. Sci. 1989;60 (Jan): 276-278.
4. Du, Q. Fan, C. Sun, YL., Preparation and Ocular in vitro evaluation of multiple unit floating granules of aminophylline., Chinese J. of Hospital Pharm. 1996; 16(Feb):54- 56.
5. Altaf, S. and Jones D. B., Development of ophthalmic sustained release formulation of Prednisolone , Pharm. Res., 1998; 15:119 – 1201.
6. Abrahamsson, B., Alpsten, M., Bake, B., Larsson, A. and Sjogren, J., In-vitro and in-vivo erosion of two different hydrophilic Ocular drug delivery system, Eur. J. Pharm. Biopharm., 1998; 46(1): 69 – 75.
7. Shivakumar H.G., Vishakante Gowda D. and Pramod Ku. T.M., “occular controlled drug delivery systems for prolonged occular residence: A review” Ind. J. Pharm. Educ. 2004; 38(4):177.
8. Choi, BY. Park, HJ. Hwang, SJ. Park, JB., Preparation of alginate beads for Ocular drug delivery system : effects of CO(2) gas-forming agents., Int. J. of Pharm. 2002; 239(Jun):81-91.
9. Timmermans J, Moes AJ, “Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy”, J. Pharm. Sci., 2008, 18-24.
10. PMojaverian P, Vlasses PH, Kellner PE, Rocci ML, Jr., “Effects of gender, posture, age on gastric residence time of an indigestible solids: pharmaceutical considerations”, Pharm. Res., 2010; 10: 639-644.
11. Panchal HA, Tiwari AK. Novel Approach of Ocular Drug Delivery Technology: An Review. Journal of Pharmaceutical Science and Technology 2012; 4(4):892–904.
12. Divya A, Kavitha K, Kumar MR, Dakshayani S, Jagadeesh SSD. Ocular Drug Delivery System: An overview. Journal of Applied Pharmaceutical Science 2011; 01(08):43-47
13. Shiyani B, Gattani S, Surana S. Formulation and evaluation of Ciprofloxacin eye drops AAPS Pharm Sci Tech 2008 ; 9(3):818-27
14. Deshpande RD, Gowda DV, Mahammed N, Deepak N. Maramwar. Conjuctival eye disorder: a review. IJPSR 2011; 2(10): 2534-2544
15. European Society of Ocular Diseases -European Society of Opthalmology guidelines for the management of conjuctival disorders. 2003; 21:1011–1053.
Statistics
497 Views | 480 Downloads
How to Cite
1.
Sarangi D, Mekap S, Panda S, Ghose D, Rana R, Mahapatra M. FORMULATION AND DEVELOPMENT OF KETOROLAC TROMETHAMINE OPHTHALMIC SOLUTION. JDDT [Internet]. 14May2018 [cited 5Aug.2021];8(3):78-1. Available from: https://jddtonline.info/index.php/jddt/article/view/1710